S1862 Microalbuminuria in Nondiabetic Patients With Nonalcoholic Fatty Liver Disease: Association With Liver Fibrosis

Yılmaz, Yusuf; Alahdab, Yeşim Özen; Yönal, Oya; Kurt, Ramazan; Kedrah, Alla Eldeen; Çelikel, Çiğdem; Duman, Deniz; Özdoğan, Osman; İmeryüz, Neşe; Avşar, Erol; Kalaycı, Cem

doi:10.1016/s0016-5085(10)63709-2

Cited by 5 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NASH is an advanced form of NAFLD. Currently, although many researchers have reported that several medicines such as sodium–glucose cotransporter 2 inhibitors, dipeptidyl peptidase 4 inhibitors, and PPAR agonists have protective effects against NASH [31–33], no pharmacological therapies have been approved yet. NAFLD is predicted to affect more than 25% of the adult population by 2030 [34, 35].…”

Section: Discussionmentioning

confidence: 99%

“…Several medicines and pathways have been suggested to exert therapeutic effects against NASH, focusing on fat accumulation in the liver, metabolic stress, oxidative stress, inflammation, and fibrotic processes [31][32][33]50]. PPARα, a member of the nuclear receptor family, is considered to be a major operator of lipid metabolic homeostasis in the liver, and the inhibition of its expression is directly related to the pathogenesis of NASH [51].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sasa veitchii extract alleviates nonalcoholic steatohepatitis in methionine–choline deficient diet‐induced mice by regulating peroxisome proliferator‐activated receptor alpha

Yoshioka,

Wu,

Moriishi

et al. 2023

Traditional & Kampo Medicine

View full text Add to dashboard Cite

AimNonalcoholic steatohepatitis (NASH) is a pandemic liver disease. This study aimed to explore the protective effects of Sasa veitchii extract (SE) in a mouse model of methionine–choline‐deficient (MCD) diet‐induced NASH.MethodsEight‐week‐old male C57BL/6J mice were fed a normal diet or an MCD diet for 8 weeks (0–8 weeks). SE (0.1 mL) was administered orally once daily for the latter period (4 weeks; 5–8 weeks). Body weight was measured weekly. The mice were euthanized and plasma samples were collected. Livers were collected and weighed.ResultsThe MCD diet decreased the liver/body weight ratio, elevated plasma alanine aminotransferase and aspartate aminotransferase levels, and increased liver oxidative stress, fibrosis, and inflammation. These changes were alleviated by SE administration. We also found that the MCD‐induced increase in triglycerides and lipid droplets in the liver was attenuated by SE. Furthermore, MCD‐induced glutathione peroxidase‐4 and peroxisome proliferator‐activated receptor‐alpha downregulation was sustained by SE administration.ConclusionOur results showed that SE protected mice against MCD‐induced hepatic injury, including oxidative stress and inflammation, by modulating peroxisome proliferator‐activated receptor alpha activation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Sasa veitchii extract alleviates nonalcoholic steatohepatitis in methionine–choline deficient diet‐induced mice by regulating peroxisome proliferator‐activated receptor alpha

Yoshioka,

Wu,

Moriishi

et al. 2023

Traditional & Kampo Medicine

View full text Add to dashboard Cite

show abstract

“…Generally, both oral and injectable glucose-lowering medication is considered safe in patients with noncirrhotic chronic liver disease, including patients with autoimmune liver disease [47][48][49]104]. Indeed, improvement in NAFLD has been demonstrated with the example of dipeptidyl peptidase-4 inhibitors [105][106][107] and GLP-1 receptor agonists [108,109]; drugs that could be used in combination with the specific treatments for autoimmune liver disease.…”

Section: Diabetes Treatment In Autoimmune Liver Diseasementioning

confidence: 99%

Autoimmune liver diseases and diabetes

Jensen

Ytting

Winther-Sørensen

et al. 2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Autoimmune liver diseases include autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. They are chronic, heterogenous diseases affecting the liver which is a key metabolic organ that ensures glucose homeostasis. It is well known that patients with other chronic liver diseases such as cirrhosis and nonalcoholic fatty liver disease (NAFLD) display glucose disturbances like insulin resistance and have an increased risk of diabetes. Previous evidence on glucose disturbances in patients with autoimmune liver disease is scarce but does point towards a potentially increased risk of type 1 diabetes and type 2 diabetes. The underlying mechanisms are unknown but may reflect genetic predisposition, concurrent NAFLD and or cirrhosis development, and treatment (steroid) related impairment of glucose homeostasis. Therefore, increased awareness and surveillance of diabetes development in patients with autoimmune liver disease may be important. Overall, detection and treatment of diabetes generally follow the usual diabetes guidelines; however, in patients with advanced liver cirrhosis, HbA1c may not be a reliable marker of average glucose levels, and treatment with insulin is generally recommended. In addition, it has recently been suggested that sodium–glucose cotransporter 2 inhibitors may be beneficial in treating refractory ascites. Further research on diabetes risk in autoimmune liver disease is warranted.

show abstract

“…90 While in diabetic or high fat diet-fed mice these drugs have been shown to reduce liver steatosis, 91,92 in humans there were no benefits on NAFLD with sitagliptin and linagliptin treatment compared to placebo and other glucose-lowering agents. [93][94][95][96][97][98][99] Considering the weight neutrality of DPP-4i, we can comprehend why these drugs have no effect on NAFLD treatment. This strengthens the hypothesis of the fundamental role of fat mass reduction, consequent lipid redistribution and improved FFA utilisation as keys to NAFLD improvement.…”

Section: Dipeptidyl Peptidase-4 Inhibitorsmentioning

confidence: 99%

“…These drugs have been actively studied in 7 trials in patients at risk of or with NAFLD, but most have not been shown to improve biopsy‐proven or imaging detected NAFLD 90 . While in diabetic or high fat diet‐fed mice these drugs have been shown to reduce liver steatosis, 91,92 in humans there were no benefits on NAFLD with sitagliptin and linagliptin treatment compared to placebo and other glucose‐lowering agents 93–99 …”

Section: Dipeptidyl Peptidase‐4 Inhibitorsmentioning

confidence: 99%

Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis

Ciccarelli

Giuseppe

Cinti

et al. 2023

Diabetes Metabolism Res

View full text Add to dashboard Cite

Non‐alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D) are metabolic disorders connected by common pathophysiological mechanisms. Since insulin resistance (IR) and metabolic alterations are common to both conditions, almost all glucose‐lowering agents which improve IR have also been studied in patients with NAFLD. Some have shown great efficacy, others none. Thus, the mechanisms behind the efficacy of these drugs in improving hepatic steatosis, steatohepatitis, and eventually fibrosis remain controversial. Glycaemic control improves T2D, but probably has limited effects on NAFLD, as all glucose‐lowering agents ameliorate glucose control but only a few improve NAFLD features. In contrast, drugs that either improve adipose tissue function, reduce lipid ingestion, or increase lipid oxidation are particularly effective in NAFLD. We therefore hypothesise that improved free fatty acid metabolism may be the unifying mechanism behind the efficacy of some glucose‐lowering agents on NAFLD and may represent the key to NAFLD treatment.

show abstract

S1862 Microalbuminuria in Nondiabetic Patients With Nonalcoholic Fatty Liver Disease: Association With Liver Fibrosis

Cited by 5 publications

References 0 publications

Sasa veitchii extract alleviates nonalcoholic steatohepatitis in methionine–choline deficient diet‐induced mice by regulating peroxisome proliferator‐activated receptor alpha

Sasa veitchii extract alleviates nonalcoholic steatohepatitis in methionine–choline deficient diet‐induced mice by regulating peroxisome proliferator‐activated receptor alpha

Autoimmune liver diseases and diabetes

Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis

Contact Info

Product

Resources

About